Last $1.60 USD
Change Today 0.00 / 0.00%
Volume 475.2K
ISR On Other Exchanges
Symbol
Exchange
NYSE Amex
Berlin
As of 8:04 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

isoray inc (ISR) Snapshot

Open
$1.60
Previous Close
$1.60
Day High
$1.60
Day Low
$1.53
52 Week High
03/20/14 - $3.77
52 Week Low
12/23/13 - $0.46
Market Cap
87.8M
Average Volume 10 Days
489.1K
EPS TTM
$-0.08
Shares Outstanding
54.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ISORAY INC (ISR)

Related News

No related news articles were found.

isoray inc (ISR) Related Businessweek News

No Related Businessweek News Found

isoray inc (ISR) Details

IsoRay, Inc develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces Proxcelan Cesium-131 brachytherapy seeds for the treatment of prostate, lung, head and neck, colorectal, brain, pelvic/abdominal, and gynecological cancers, as well as ocular melanoma. It also offers GliaSite radiation therapy system, a balloon catheter device, which is used to treat brain cancer, including primary and recurrent gliomas and metastic brain tumors. The company is headquartered in Richland, Washington.

37 Employees
Last Reported Date: 09/29/14

isoray inc (ISR) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $334.7K
Chief Financial Officer
Total Annual Compensation: $117.8K
Vice President
Total Annual Compensation: $167.9K
Vice President of Research & Development and ...
Total Annual Compensation: $154.5K
Compensation as of Fiscal Year 2014.

isoray inc (ISR) Key Developments

IsoRay, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2014

IsoRay, Inc. reported unaudited consolidated earnings results for the first quarter ended September 30, 2014. For the quarter, the company reported net product sales of $1,042,101 compared to $1,049,915 a year ago. Operating loss was $1,161,106 compared to $1,234,519 a year ago. Net loss applicable to common shareholders was of $788,520 or $0.01 per basic and diluted share compared to $1,999,942 or $0.06 per basic and diluted share a year ago.

Varian Medical Reportedly To Buy IsoRay

IsoRay, Inc. (AMEX:ISR) could be a potential takeover target for Varian Medical Systems, Inc. (NYSE:VAR), reported dealReporter.

IsoRay, Inc. Announces Consolidated Financial Results for the Year Ended June 30, 2014

IsoRay, Inc. announced consolidated financial results for the year ended June 30, 2014. For the year, product sales were $4,219,158 against $4,525,233 a year ago. Operating loss was $4,588,218 against $4,067,253 a year ago. Net loss was $5,959,122 or $0.16 per basic and diluted share against $3,856,596 or $0.11 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISR:US $1.60 USD 0.00

ISR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Accuray Inc $7.54 USD +0.14
CR Bard Inc $169.50 USD -2.08
Elekta AB kr81.00 SEK 0.00
Varian Medical Systems Inc $88.04 USD +0.87
View Industry Companies
 

Industry Analysis

ISR

Industry Average

Valuation ISR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.3x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISORAY INC, please visit www.isoray.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.